MISAA
About this raise
MISAA, with a valuation of $10 million, is raising funds on NetCapital. The company is developing a 15-minute blood test for tacrolimus, required for organ transplant patients. MISAA’s TAC Assay will be a rapid test that will be usable in labs, POC, and homes and could enhance transplant outcomes for patients. The rapid test is also expected to impact the lives of recipients, caregivers, and service providers. Reuben Sandler founded MISAA in July 2023. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1 million. The campaign proceeds will be used for labor, clinical trials, product development, materials, consulting, admin, and overhead.
Investment Overview
Invested $13,158 :
Deal Terms
Company & Team
Company
- Year Founded
- 2023
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- Grants
- $4,000,000
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
12/20/2024 | Netcapital | $10,000,000 | $13,158 | Equity - Common | Funded | RegCF |